Three-month, Single-center Study to Identify Biomarkers (Plasma Exosomal miRNAs) and Mechanism of Response (Basophil Transcriptome Analysis) to Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria

Trial Profile

Three-month, Single-center Study to Identify Biomarkers (Plasma Exosomal miRNAs) and Mechanism of Response (Basophil Transcriptome Analysis) to Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Urticaria
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 27 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
    • 27 Jun 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jun 2018.
    • 01 Nov 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top